Companies Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International (KNSA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Kiniksa Pharmaceuticals International, plc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers56th pct.Of 16 peer CEOs
CEO pay, last three years
- $5,297,067FY2023
- $7,129,792FY2024
- $10,782,661FY2025
CEO total pay was $10,782,661 in fiscal 2025, up from $7,129,792 in fiscal 2024.
FY2025: salary $943,129 · bonus $0 · stock awards $3,798,021 · option awards $4,743,446
Executives and directors
Eben Tessari · ExecutiveJohn Paolini · EVPMark Ragosa · CFORoss Moat · COOSanj Patel · CEOBarry D. Quart · Independent DirectorFelix J. Baker · Lead Independent DirectorG. Bradley Cole · Independent DirectorKimberly J. Popovits · Independent DirectorM. Cantey Boyd · Independent DirectorRichard S. Levy · Independent DirectorStephen R. Biggar · Independent DirectorThomas R. Malley · Independent DirectorTracey L. McCain · Independent Director
Frequently asked questions
Who was the highest-paid executive at Kiniksa Pharmaceuticals International, plc in fiscal 2025?
As disclosed, Sanj Patel (Chief Executive Officer and Chairman of the Board) was the highest-paid executive at Kiniksa Pharmaceuticals International, plc in fiscal 2025, with total compensation of $10,782,661.
How does Kiniksa Pharmaceuticals International, plc's chief executive pay compare to its disclosed peer group?
As disclosed, Sanj Patel's total compensation ranked at the 56th percentile of Kiniksa Pharmaceuticals International, plc's disclosed peer group.
What is Kiniksa Pharmaceuticals International, plc's CEO-to-median employee pay ratio?
As disclosed, Kiniksa Pharmaceuticals International, plc's CEO-to-median employee pay ratio was 35:1.
How did shareholders vote on Kiniksa Pharmaceuticals International, plc's executive compensation?
As disclosed, 97.3% of shareholders supported Kiniksa Pharmaceuticals International, plc's executive compensation in the latest say-on-pay vote.
How much does Kiniksa Pharmaceuticals International, plc spend in total on board compensation for fiscal 2025?
As disclosed, Kiniksa Pharmaceuticals International, plc reported total board compensation of $1,428,293 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sanj Patel | $943,129 | $0 | $3,798,021 | $4,743,446 | $1,284,065 | $0 | $14,000 | $10,782,661 |
| Chief Executive Officer and Chairman of the Board | ||||||||
| Ross Moat | 586,269 | 0 | 1,084,019 | 1,356,609 | 533,326 | 0 | 77,778 | 3,638,001 |
| Executive Vice President and Chief Commercial Officer | ||||||||
| John Paolini | 585,092 | 0 | 1,084,019 | 1,356,609 | 530,935 | 0 | 14,000 | 3,570,655 |
| Executive Vice President and Chief Medical Officer | ||||||||
| Eben Tessari | 586,460 | 0 | 1,084,019 | 1,356,609 | 533,278 | 0 | 5,865 | 3,566,231 |
| Executive Vice President and Chief Operating Officer | ||||||||
| Mark Ragosa | 552,795 | 0 | 978,099 | 1,221,456 | 516,705 | 0 | 14,000 | 3,283,055 |
| Senior Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Sanj Patel | $10,782,661 | $7,129,792 | $5,297,067 | ↑ +3,652,869 |
| Ross Moat | 3,638,001 | 2,337,130 | 1,631,209 | ↑ +1,300,871 |
| John Paolini | 3,570,655 | 2,431,016 | 1,789,109 | ↑ +1,139,639 |
| Eben Tessari | 3,566,231 | 2,353,166 | 1,752,096 | ↑ +1,213,065 |
| Mark Ragosa | 3,283,055 | 2,201,447 | 1,766,757 | ↑ +1,081,608 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to reward the achievement of our strategic corporate objectives and creation of long-term shareholder value by emphasizing the achievement of short-term goals while sustaining long-term growth. We align executive interests with shareholders through a significant portion of target total direct compensation delivered in long-term equity awards, including performance-based awards, and ensure our pay practices are competitive with our peer group and industry.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Sanj Patel | PSU | 2025-04-01 | 34,435 | 68,869 | — | 137,738 | $1,895,143 |
| Mark Ragosa | RSU | 2025-04-01 | — | — | 7,382 | — | 160,706 |
| Mark Ragosa | RSU | 2025-09-01 | — | — | 12,275 | — | 411,090 |
| Sanj Patel | RSU | 2025-04-01 | — | — | 34,435 | — | 749,650 |
| Sanj Patel | RSU | 2025-09-01 | — | — | 34,435 | — | 1,153,228 |
| Ross Moat | OPTION | 2025-09-01 | — | — | 39,364 | — | 818,429 |
| Ross Moat | RSU | 2025-04-01 | — | — | 9,828 | — | 213,956 |
| Ross Moat | RSU | 2025-09-01 | — | — | 9,828 | — | 329,140 |
| Ross Moat | PSU | 2025-04-01 | 9,829 | 19,657 | — | 39,314 | 540,924 |
| John Paolini | OPTION | 2025-04-01 | — | — | 39,364 | — | 538,181 |
| John Paolini | OPTION | 2025-09-01 | — | — | 39,364 | — | 818,429 |
| John Paolini | RSU | 2025-04-01 | — | — | 9,828 | — | 213,956 |
| John Paolini | RSU | 2025-09-01 | — | — | 9,828 | — | 329,140 |
| John Paolini | PSU | 2025-04-01 | 9,829 | 19,657 | — | 39,314 | 540,924 |
| Eben Tessari | RSU | 2025-04-01 | — | — | 9,828 | — | 213,956 |
| Eben Tessari | OPTION | 2025-05-01 | 8,172 | 16,344 | — | 16,344 | — |
| Eben Tessari | RSU | 2025-09-01 | — | — | 9,828 | — | 329,140 |
| Eben Tessari | PSU | 2025-04-01 | 9,829 | 19,657 | — | 39,314 | 540,924 |
| Mark Ragosa | OPTION | 2025-04-01 | — | — | 29,480 | — | 403,048 |
| Mark Ragosa | PSU | 2025-04-01 | 7,383 | 14,765 | — | 29,530 | 406,303 |
| Sanj Patel | OPTION | 2025-04-01 | — | — | 137,638 | — | 1,878,082 |
| Eben Tessari | OPTION | 2025-09-01 | — | — | 39,364 | — | 818,429 |
| Sanj Patel | OPTION | 2025-09-01 | — | — | 137,638 | — | 2,861,673 |
| Ross Moat | OPTION | 2025-04-01 | — | — | 39,364 | — | 538,181 |
| Eben Tessari | OPTION | 2025-04-01 | — | — | 39,364 | — | 538,181 |
| Mark Ragosa | OPTION | 2025-09-01 | — | — | 39,363 | — | 818,408 |
| John Paolini | PSU | 2025-05-01 | 5,078 | 10,155 | — | 10,155 | — |
| Ross Moat | PSU | 2025-05-01 | 5,101 | 10,201 | — | 10,201 | — |
| Ross Moat | OPTION | 2025-05-01 | 8,173 | 16,346 | — | 16,346 | — |
| John Paolini | OPTION | 2025-05-01 | 8,137 | 16,273 | — | 16,273 | — |
| Eben Tessari | PSU | 2025-05-01 | 5,100 | 10,199 | — | 10,199 | — |
| Mark Ragosa | PSU | 2025-05-01 | 4,672 | 9,344 | — | 9,344 | — |
| Mark Ragosa | OPTION | 2025-05-01 | 7,487 | 14,974 | — | 14,974 | — |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Sanj Patel | $1,902,878 | $1,895,143 | $4,739,755 | 22.2% |
| Mark Ragosa | 571,796 | 406,303 | 1,221,456 | 18.5% |
| Ross Moat | 543,096 | 540,924 | 1,356,610 | 22.2% |
| John Paolini | 543,096 | 540,924 | 1,356,610 | 22.2% |
| Eben Tessari | 543,096 | 540,924 | 1,356,610 | 22.2% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ross Moat | RSU | 2,477 | — | $102,176 |
| John Paolini | RSU | 2,497 | — | 103,001 |
| Mark Ragosa | RSU | 2,694 | — | 111,128 |
| Eben Tessari | RSU | 2,726 | — | 112,448 |
| Ross Moat | RSU | 3,222 | — | 132,908 |
| John Paolini | RSU | 3,248 | — | 133,980 |
| Mark Ragosa | RSU | 3,500 | — | 144,375 |
| Eben Tessari | RSU | 3,545 | — | 146,231 |
| Mark Ragosa | PSU | 4,558 | — | 188,018 |
| Mark Ragosa | RSU | 4,773 | — | 196,886 |
| Mark Ragosa | PSU | 4,786 | — | 197,423 |
| John Paolini | PSU | 4,954 | — | 204,353 |
| Ross Moat | Option | 4,954 | 11.1 | — |
| Eben Tessari | PSU | 4,975 | — | 205,219 |
| Ross Moat | PSU | 4,976 | — | 205,260 |
| John Paolini | Option | 4,994 | 11.1 | — |
| Mark Ragosa | PSU | 5,092 | — | 210,045 |
| John Paolini | PSU | 5,201 | — | 214,541 |
| Ross Moat | RSU | 5,221 | — | 215,366 |
| Eben Tessari | PSU | 5,224 | — | 215,490 |
| Ross Moat | PSU | 5,225 | — | 215,531 |
| Eben Tessari | RSU | 5,235 | — | 215,944 |
| John Paolini | RSU | 5,250 | — | 216,563 |
| Mark Ragosa | Option | 5,388 | 11.1 | — |
| Eben Tessari | Option | 5,451 | 11.1 | — |
| Ross Moat | PSU | 5,569 | — | 229,721 |
| Eben Tessari | PSU | 5,585 | — | 230,381 |
| John Paolini | PSU | 5,600 | — | 231,000 |
| Mark Ragosa | RSU | 7,382 | — | 304,508 |
| Sanj Patel | PSU | 7,987 | — | 329,464 |
| Sanj Patel | PSU | 8,386 | — | 345,923 |
| John Paolini | RSU | 9,828 | — | 405,405 |
| Eben Tessari | RSU | 9,828 | — | 405,405 |
| Ross Moat | RSU | 9,828 | — | 405,405 |
| Sanj Patel | RSU | 9,991 | — | 412,129 |
| Ross Moat | Option | 11,148 | 11.97 | — |
| John Paolini | Option | 11,236 | 11.97 | — |
| Mark Ragosa | Option | 12,123 | 11.97 | — |
| Eben Tessari | Option | 12,266 | 11.97 | — |
| Mark Ragosa | RSU | 12,275 | — | 506,344 |
| Ross Moat | Option | 12,889 | 10.76 | — |
| Sanj Patel | RSU | 12,962 | — | 534,683 |
| John Paolini | Option | 12,991 | 10.76 | — |
| Mark Ragosa | Option | 14,016 | 10.76 | — |
| Eben Tessari | Option | 14,181 | 10.76 | — |
| Mark Ragosa | PSU | 14,765 | — | 609,056 |
| Ross Moat | Option | 16,916 | 17.76 | — |
| John Paolini | Option | 17,050 | 17.76 | — |
| Mark Ragosa | Option | 18,396 | 17.76 | — |
| Eben Tessari | Option | 18,612 | 17.76 | — |
| Sanj Patel | RSU | 18,712 | — | 771,870 |
| Mark Ragosa | Option | 19,337 | 18.06 | — |
| John Paolini | PSU | 19,657 | — | 810,851 |
| Eben Tessari | PSU | 19,657 | — | 810,851 |
| Ross Moat | PSU | 19,657 | — | 810,851 |
| Sanj Patel | Option | 19,982 | 11.1 | — |
| Sanj Patel | PSU | 20,000 | — | 825,000 |
| Ross Moat | Option | 21,058 | 18.06 | — |
| Eben Tessari | Option | 21,174 | 18.06 | — |
| John Paolini | Option | 21,203 | 18.06 | — |
| Mark Ragosa | Option | 22,790 | 26.74 | — |
| Ross Moat | Option | 24,818 | 26.74 | — |
| Eben Tessari | Option | 24,956 | 26.74 | — |
| John Paolini | Option | 24,990 | 26.74 | — |
| Mark Ragosa | Option | 29,480 | 21.77 | — |
| Sanj Patel | RSU | 34,435 | — | 1,420,444 |
| Mark Ragosa | Option | 39,363 | 33.49 | — |
| John Paolini | Option | 39,364 | 21.77 | — |
| Eben Tessari | Option | 39,364 | 21.77 | — |
| Ross Moat | Option | 39,364 | 21.77 | — |
| John Paolini | Option | 39,364 | 33.49 | — |
| Eben Tessari | Option | 39,364 | 33.49 | — |
| Ross Moat | Option | 39,364 | 33.49 | — |
| Sanj Patel | Option | 44,960 | 11.97 | — |
| Sanj Patel | Option | 51,832 | 10.76 | — |
| Sanj Patel | Option | 68,030 | 17.76 | — |
| Sanj Patel | PSU | 68,869 | — | 2,840,846 |
| Sanj Patel | Option | 75,686 | 18.06 | — |
| Sanj Patel | Option | 89,202 | 26.74 | — |
| Sanj Patel | Option | 137,638 | 21.77 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Richard S. LevyIndependent · Science (Chair) | $69,998 | $111,470 | $255,162 | $0 | $30,000 | $466,630 |
| Felix J. BakerIndependent · Lead Independent Director · Governance · Science | 93,999 | 81,479 | 255,162 | 0 | 0 | 430,640 |
| Barry D. QuartIndependent · Audit · Compensation · Science | 77,999 | 81,479 | 255,162 | 0 | 0 | 414,640 |
| Thomas R. MalleyIndependent · Audit (Chair) · Governance | 74,999 | 81,479 | 255,162 | 0 | 0 | 411,640 |
| Kimberly J. PopovitsIndependent · Compensation (Chair) | 69,999 | 81,479 | 255,162 | 0 | 0 | 406,640 |
| Stephen R. BiggarIndependent · Governance (Chair) · Science | 68,999 | 81,479 | 255,162 | 0 | 0 | 405,640 |
| G. Bradley ColeIndependent · Audit | 59,999 | 81,479 | 255,162 | 0 | 0 | 396,640 |
| Tracey L. McCainIndependent · Audit | 59,999 | 81,479 | 255,162 | 0 | 0 | 396,640 |
| M. Cantey BoydIndependent · Compensation | 59,000 | 81,479 | 255,162 | 0 | 0 | 395,641 |
| Sanj K. PatelEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $340,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $634,991 |
| Equity awards (grant-date value) | $763,302 |
| All other compensation | $30,000 |
| Total cost of the board | $1,428,293 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Kiniksa Pharmaceuticals International as a peer
Companies that benchmark against KNSA
4 companies name KNSA as a compensation peer
The list of companies that name KNSA as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
TVTX Travere TherapeuticsVCEL VericelBCRX BioCryst PharmaceuticalsACAD Acadia PharmaceuticalsAGIO Agios PharmaceuticalsFOLD Amicus TherapeuticsAPLS Apellis PharmaceuticalsARDX ArdelyxBBIO BridgeBio PharmaCORT Corcept TherapeuticsHRMY Harmony Biosciences HoldingsIRWD Ironwood PharmaceuticalsMGNX MacroGenicsRYTM Rhythm PharmaceuticalsSAGE Sage TherapeuticsSUPN Supernus Pharmaceuticals
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rhythm Pharmaceuticals | 2025 | David Meeker | $807,692 | $8,274,785 | $7,688,560 | $759,488 | $17,544,525 |
| 2 | Supernus Pharmaceuticals | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 3 | Corcept Therapeutics | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 4 | BridgeBio Pharma | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 5 | BioCryst Pharmaceuticals | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 6 | Vericel | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 7 | Apellis Pharmaceuticals | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 8 | Kiniksa Pharmaceuticals International, plc | 2025 | Sanj Patel | 943,129 | 3,798,021 | 4,743,446 | 1,284,065 | 10,782,661 |
| 9 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 10 | Travere Therapeutics | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 11 | Acadia Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 12 | Harmony Biosciences Holdings | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 13 | Ardelyx | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 14 | Sage Therapeutics | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 15 | Agios Pharmaceuticals | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 16 | MacroGenics | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 17 | Ironwood Pharmaceuticals | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc | not disclosed | Option 50 · RSU 25 · PSU 25 | not disclosed | Compensia, Inc. |
| Acadia Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Agios Pharmaceuticals | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Amicus Therapeutics | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Ardelyx | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| BioCryst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Corcept Therapeutics | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Harmony Biosciences Holdings | 100% | not disclosed | not disclosed | Pay Governance |
| Ironwood Pharmaceuticals | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| MacroGenics | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Rhythm Pharmaceuticals | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Sage Therapeutics | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| Supernus Pharmaceuticals | not disclosed | not disclosed | No | Aon |
| Travere Therapeutics | 150% | not disclosed | No | Aon |
| Vericel | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-29 | 48,145,082 | 1,334,278 | 8,495 | 97.3% | Passed |
| 2025 | 2025-06-03 | 49,107,201 | 550,666 | 20,575 | 98.89% | Passed |
| 2024 | 2024-06-05 | 46,903,551 | 469,616 | 324,979 | 99.01% | Passed |
| 2023 | 2023-06-06 | 40,423,385 | 1,270,222 | 380,052 | 96.95% | Passed |
| 2022 | 2022-06-29 | 41,519,436 | 333,395 | 56,571 | 99.2% | Passed |
| 2021 | 2021-06-29 | 40,582,357 | 625,207 | 24,695 | 98.48% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-29 | 97.3%a |
| 2025 | 2025-06-03 | 98.89%b |
| 2024 | 2024-06-05 | 99.01%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.”.
b. Approved under the standard stated in the filing — “ Abstentions and broker non-votes will have no effect on the outcome of the vote on this proposal.”.
c. Approved under the standard stated in the filing — “ Abstentions and broker non-votes will have no effect on the outcome of the vote on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 35 : 1 |
|---|---|
| CEO total compensation | $10,782,661 |
| Median employee compensation | $310,707 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Kimberly J. Popovits | Director | 2026-05-29 | A | 12,158 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly J. Popovits | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-05-29 | D | 2,799 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-29 | A | 36,474 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-05-29 | D | 2,799 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| Richard S. Levy | Director | 2026-05-29 | D | 2,799 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas R. Malley | Director | 2026-05-29 | A | 2,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas R. Malley | Director | 2026-05-29 | A | 12,158 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas R. Malley | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | Director | 2026-05-29 | D | 2,799 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-05-29 | A | 2,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-05-29 | A | 12,158 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | Director | 2026-05-29 | A | 12,158 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-29 | A | 36,474 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-29 | A | 6,078 | 0 | 0 | Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-05-29 | A | 12,158 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard S. Levy | Director | 2026-05-29 | A | 2,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | Director | 2026-05-29 | A | 2,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-06-01 | D | 900,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-06-01 | A | 900,000 | — | — | Common | Form 4 ↗ |
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 14,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 82,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-01 | — | 2,552 | — | — | 1 insider, 2 accrual rows | ||
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 2,188 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 2,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-07-15 | A | 279 | 34 | 9,347 | Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-07-29 | D | 3,673 | 81 | 299,092 | Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-07-29 | D | 4,500 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-01 | — | 806 | — | — | 1 insider, 2 accrual rows | ||
| Richard S. Levy | Director | 2026-08-01 | A | 403 | — | — | Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-08-19 | D | 2,600 | 0 | 0 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 2,644 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 5,531 | 79 | 438,498 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 2,362 | — | — | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | D | 2,477 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-01 | — | 10,066 | — | — | 3 insiders, 6 accrual rows | ||
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 36,950 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 1,611 | — | — | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | D | 2,457 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | D | 4,029 | 79 | 319,419 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 1,624 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 120,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 8,609 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 9,991 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 6,237 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 8,609 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 6,237 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 6,481 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 9,991 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 31,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 7,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | D | 4,404 | 79 | 349,149 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 3,069 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 1,591 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 1,750 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 2,694 | — | — | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | D | 4,007 | 79 | 317,675 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 1,740 | — | — | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 3,650 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 2,457 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 9,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 6,237 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 8,609 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 6,237 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 6,481 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 9,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 6,481 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 8,609 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 120,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 30,050 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | D | 2,497 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 26,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 2,457 | — | — | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 1,750 | — | — | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 2,497 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | D | 2,694 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | D | 3,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | D | 2,457 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 3,932 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 2,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 2,362 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 14,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 2,558 | — | — | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 3,932 | — | — | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 2,644 | — | — | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 2,477 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 6,481 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 30,050 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 15,144 | 79 | 1,200,616 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 15,144 | 79 | 1,200,616 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 9,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 6,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-03 | D | 4,600 | 80 | 369,380 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 10,895 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 16,112 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-30 | — | 1,658 | — | — | 1 insider, 1 accrual row | ||
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 3,760 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 21,059 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 16,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 2,575 | 98 | 251,732 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 1,760 | 97 | 170,896 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 3,672 | 96 | 352,622 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 6,282 | 95 | 596,287 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 8,430 | 94 | 792,167 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 15,114 | 93 | 1,402,730 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 37,775 | 92 | 3,475,300 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 10,895 | 18 | 196,764 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 16,112 | 18 | 286,149 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 1,658 | 13 | 21,504 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 3,760 | 12 | 45,007 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 21,059 | 11 | 233,755 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 16,111 | 11 | 173,354 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 39,042 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 38,545 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 2,155 | 98 | 210,694 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 1,925 | 97 | 186,841 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 4,000 | 96 | 383,880 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 4,821 | 95 | 457,320 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 6,841 | 94 | 642,438 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 16,056 | 93 | 1,490,800 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 41,789 | 92 | 3,845,424 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | A | 39,042 | 18 | 699,633 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | A | 38,545 | 31 | 1,192,197 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 47,530 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 1,440 | 98 | 141,350 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 2,316 | 97 | 225,439 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 4,490 | 96 | 430,905 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 8,888 | 95 | 841,871 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 15,903 | 94 | 1,488,839 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 18,685 | 93 | 1,733,407 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 41,169 | 92 | 3,787,960 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | A | 47,530 | 9 | 419,690 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 4,065 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 4,689 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 7,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 3,932 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 5,350 | 98 | 522,909 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 1,691 | 97 | 164,213 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 3,145 | 96 | 302,172 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 3,705 | 95 | 351,456 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 9,508 | 94 | 895,654 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 6,831 | 93 | 633,712 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 6,030 | 92 | 553,976 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | A | 4,065 | 18 | 72,194 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | A | 7,209 | 12 | 86,292 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | A | 3,932 | 11 | 43,645 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | A | 4,689 | 11 | 50,454 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 6,263 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 12,302 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 9,412 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 722 | 94 | 67,904 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 11,642 | 93 | 1,084,452 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 8,932 | 92 | 822,191 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 6,681 | 91 | 609,508 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | A | 6,263 | 23 | 143,360 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | A | 12,302 | 22 | 267,815 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | A | 9,412 | 18 | 169,981 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 9,636 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 12,123 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 5,388 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 9,636 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 220 | 94 | 20,682 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 12,034 | 93 | 1,120,726 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 10,502 | 92 | 966,499 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 14,027 | 91 | 1,282,068 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | A | 9,636 | 18 | 171,135 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | A | 12,123 | 12 | 145,112 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | A | 5,388 | 11 | 59,807 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | A | 9,636 | 11 | 103,683 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 11,958 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 6,455 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 704 | 94 | 66,239 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 16,810 | 93 | 1,570,390 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 899 | 92 | 83,041 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | A | 11,958 | 18 | 214,287 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | A | 6,455 | 31 | 199,653 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 53,381 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 100 | 94 | 9,397 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 26,781 | 93 | 2,492,240 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 24,188 | 92 | 2,221,184 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 38,364 | 91 | 3,492,275 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | A | 53,381 | 9 | 471,354 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 41,237 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 89,089 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 4,584 | 94 | 432,042 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 145,708 | 94 | 13,628,069 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 68,664 | 93 | 6,365,153 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 1,214 | 91 | 110,195 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | A | 41,237 | 18 | 738,967 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | A | 89,089 | 9 | 786,656 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 200 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Kimberly J. Popovits | Director | 2026-05-29 | A | 12,158 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly J. Popovits | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-05-29 | D | 2,799 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-29 | A | 36,474 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-05-29 | D | 2,799 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| Richard S. Levy | Director | 2026-05-29 | D | 2,799 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas R. Malley | Director | 2026-05-29 | A | 2,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas R. Malley | Director | 2026-05-29 | A | 12,158 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas R. Malley | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | Director | 2026-05-29 | D | 2,799 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-05-29 | A | 2,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-05-29 | A | 12,158 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-05-29 | A | 2,799 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | Director | 2026-05-29 | A | 12,158 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-29 | A | 36,474 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-05-29 | A | 6,078 | 0 | 0 | Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-05-29 | A | 12,158 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard S. Levy | Director | 2026-05-29 | A | 2,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | Director | 2026-05-29 | A | 2,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-06-01 | D | 900,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-06-01 | A | 900,000 | — | — | Common | Form 4 ↗ |
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 14,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 82,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 1,307 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 1,245 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 2,188 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dhiraj H. Malkani | Chief Strategy Officer | 2026-07-01 | A | 2,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-07-15 | A | 279 | 34 | 9,347 | Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-07-29 | D | 3,673 | 81 | 299,092 | Common | Form 4 ↗ |
| G. Bradley Cole | Director | 2026-07-29 | D | 4,500 | 0 | 0 | Common | Form 4 ↗ |
| Richard S. Levy | Director | 2026-08-01 | A | 403 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard S. Levy | Director | 2026-08-01 | D | 403 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard S. Levy | Director | 2026-08-01 | A | 403 | — | — | Common | Form 4 ↗ |
| Barry D. Quart | Director | 2026-08-19 | D | 2,600 | 0 | 0 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 2,644 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 5,531 | 79 | 438,498 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 2,362 | — | — | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | D | 2,477 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | D | 1,611 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | D | 1,740 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 36,950 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 1,611 | — | — | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | D | 1,624 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | D | 1,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | D | 2,457 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | D | 4,029 | 79 | 319,419 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 1,624 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 120,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 8,609 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 9,991 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 6,237 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 8,609 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 6,237 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 6,481 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 9,991 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | D | 1,591 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 31,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 7,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | D | 4,404 | 79 | 349,149 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 3,069 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 1,591 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 1,750 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | A | 2,694 | — | — | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | D | 4,007 | 79 | 317,675 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 1,740 | — | — | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 3,650 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 2,457 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 9,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 6,237 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 8,609 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 6,237 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 6,481 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 9,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 6,481 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 8,609 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 120,150 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 30,050 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | D | 2,497 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 26,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 2,457 | — | — | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 1,750 | — | — | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 2,497 | — | — | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | D | 2,694 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | D | 1,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-09-01 | D | 3,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | D | 2,457 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 3,932 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 2,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | D | 2,362 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 14,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 2,558 | — | — | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 3,932 | — | — | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-01 | A | 2,644 | — | — | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 2,477 | — | — | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 6,481 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | A | 30,050 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 15,144 | 79 | 1,200,616 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-09-01 | D | 15,144 | 79 | 1,200,616 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-09-01 | A | 9,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-09-01 | A | 6,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-09-03 | D | 4,600 | 80 | 369,380 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 10,895 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 16,112 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 1,658 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 3,760 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 21,059 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 16,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 2,575 | 98 | 251,732 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 1,760 | 97 | 170,896 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 3,672 | 96 | 352,622 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 6,282 | 95 | 596,287 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 8,430 | 94 | 792,167 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 15,114 | 93 | 1,402,730 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | D | 37,775 | 92 | 3,475,300 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 10,895 | 18 | 196,764 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 16,112 | 18 | 286,149 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 1,658 | 13 | 21,504 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 3,760 | 12 | 45,007 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 21,059 | 11 | 233,755 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-10-30 | A | 16,111 | 11 | 173,354 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 39,042 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 38,545 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 2,155 | 98 | 210,694 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 1,925 | 97 | 186,841 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 4,000 | 96 | 383,880 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 4,821 | 95 | 457,320 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 6,841 | 94 | 642,438 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 16,056 | 93 | 1,490,800 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | D | 41,789 | 92 | 3,845,424 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | A | 39,042 | 18 | 699,633 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-10-30 | A | 38,545 | 31 | 1,192,197 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 47,530 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 1,440 | 98 | 141,350 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 2,316 | 97 | 225,439 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 4,490 | 96 | 430,905 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 8,888 | 95 | 841,871 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 15,903 | 94 | 1,488,839 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 18,685 | 93 | 1,733,407 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | D | 41,169 | 92 | 3,787,960 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-10-30 | A | 47,530 | 9 | 419,690 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 4,065 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 4,689 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 7,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 3,932 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 5,350 | 98 | 522,909 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 1,691 | 97 | 164,213 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 3,145 | 96 | 302,172 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 3,705 | 95 | 351,456 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 9,508 | 94 | 895,654 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 6,831 | 93 | 633,712 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | D | 6,030 | 92 | 553,976 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | A | 4,065 | 18 | 72,194 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | A | 7,209 | 12 | 86,292 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | A | 3,932 | 11 | 43,645 | Common | Form 4 ↗ |
| Michael R. Megna | Chief Accounting Officer | 2026-10-30 | A | 4,689 | 11 | 50,454 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 6,263 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 12,302 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 9,412 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 722 | 94 | 67,904 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 11,642 | 93 | 1,084,452 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 8,932 | 92 | 822,191 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | D | 6,681 | 91 | 609,508 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | A | 6,263 | 23 | 143,360 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | A | 12,302 | 22 | 267,815 | Common | Form 4 ↗ |
| Ross Moat | Chief Operating Officer | 2026-11-02 | A | 9,412 | 18 | 169,981 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 9,636 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 12,123 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 5,388 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 9,636 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 220 | 94 | 20,682 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 12,034 | 93 | 1,120,726 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 10,502 | 92 | 966,499 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | D | 14,027 | 91 | 1,282,068 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | A | 9,636 | 18 | 171,135 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | A | 12,123 | 12 | 145,112 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | A | 5,388 | 11 | 59,807 | Common | Form 4 ↗ |
| Mark Ragosa | Chief Financial Officer | 2026-11-02 | A | 9,636 | 11 | 103,683 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 11,958 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 6,455 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 704 | 94 | 66,239 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 16,810 | 93 | 1,570,390 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | D | 899 | 92 | 83,041 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | A | 11,958 | 18 | 214,287 | Common | Form 4 ↗ |
| John Paolini | Chief Medical Officer | 2026-11-02 | A | 6,455 | 31 | 199,653 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 53,381 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 100 | 94 | 9,397 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 26,781 | 93 | 2,492,240 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 24,188 | 92 | 2,221,184 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | D | 38,364 | 91 | 3,492,275 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-02 | A | 53,381 | 9 | 471,354 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 41,237 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 89,089 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 4,584 | 94 | 432,042 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 145,708 | 94 | 13,628,069 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 68,664 | 93 | 6,365,153 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | D | 1,214 | 91 | 110,195 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | A | 41,237 | 18 | 738,967 | Common | Form 4 ↗ |
| Sanj K. Patel | Director | 2026-11-03 | A | 89,089 | 9 | 786,656 | Common | Form 4 ↗ |
Sources (272 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Sanj Patel. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 10,782,661. View filing ↗
- Section 01, Ross Moat. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 3,638,001. View filing ↗
- Section 01, John Paolini. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 3,570,655. View filing ↗
- Section 01, Eben Tessari. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 3,566,231. View filing ↗
- Section 01, Mark Ragosa. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 52. As printed: 3,283,055. View filing ↗
- Section 03, Sanj Patel PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Ragosa RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Ragosa RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sanj Patel RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sanj Patel RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Ross Moat OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Ross Moat RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Ross Moat RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Ross Moat PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Paolini OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Paolini OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Paolini RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Paolini RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Paolini PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Eben Tessari RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Eben Tessari OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Eben Tessari RSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Eben Tessari PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Ragosa OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Ragosa PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sanj Patel OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Eben Tessari OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sanj Patel OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Ross Moat OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Eben Tessari OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Ragosa OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Paolini PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Ross Moat PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Ross Moat OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Paolini OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Eben Tessari PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Ragosa PSU. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Ragosa OPTION. DEF 14A, filed 2026-04-16. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-16. Section “CEO Pay Ratio”. As printed: 35 : 1. View filing ↗
- Section 08, Richard S. Levy. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 466,630. View filing ↗
- Section 08, Felix J. Baker. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 430,640. View filing ↗
- Section 08, Barry D. Quart. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 414,640. View filing ↗
- Section 08, Thomas R. Malley. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 411,640. View filing ↗
- Section 08, Kimberly J. Popovits. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 406,640. View filing ↗
- Section 08, Stephen R. Biggar. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 405,640. View filing ↗
- Section 08, G. Bradley Cole. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 396,640. View filing ↗
- Section 08, Tracey L. McCain. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 396,640. View filing ↗
- Section 08, M. Cantey Boyd. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 395,641. View filing ↗
- Section 08, Sanj K. Patel. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Kimberly J. Popovits 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kimberly J. Popovits 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry D. Quart 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Bradley Cole 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Bradley Cole 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard S. Levy 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas R. Malley 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas R. Malley 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas R. Malley 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry D. Quart 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry D. Quart 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry D. Quart 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Bradley Cole 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard S. Levy 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey L. McCain 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dhiraj H. Malkani 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-07-15. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Bradley Cole 2026-07-29. Form 4, filed 2026-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Bradley Cole 2026-07-29. Form 4, filed 2026-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard S. Levy 2026-08-01. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard S. Levy 2026-08-01. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard S. Levy 2026-08-01. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry D. Quart 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-09-03. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael R. Megna 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ross Moat 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Ragosa 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Paolini 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanj K. Patel 2026-11-03. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-29. Item 5.07 · say-on-pay result. As reported: 97.3% (votes for as printed: 48,145,082). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-03. Item 5.07 · say-on-pay result. As reported: 98.89% (votes for as printed: 49,107,201). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-05. Item 5.07 · say-on-pay result. As reported: 99.01% (votes for as printed: 46,903,551). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 634,991 + equity 763,302 + all other 30,000 = 1,428,293, summed across the director compensation table rows.
- Rhythm Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals's own proxy. As printed: 17,544,525. View filing ↗
- Supernus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 15,501,557. View filing ↗
- Corcept Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. View filing ↗
- BridgeBio Pharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. View filing ↗
- BioCryst Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 12,951,082. View filing ↗
- Vericel, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. View filing ↗
- Apellis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. View filing ↗
- Kiniksa Pharmaceuticals International, plc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Kiniksa Pharmaceuticals International, plc's own proxy. As printed: 10,782,661. View filing ↗
- Amicus Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. View filing ↗
- Travere Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. View filing ↗
- Acadia Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals's own proxy. As printed: 8,256,518. View filing ↗
- Harmony Biosciences Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Harmony Biosciences Holdings's own proxy. As printed: 7,899,535. View filing ↗
- Ardelyx, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. View filing ↗
- Sage Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. View filing ↗
- Agios Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. View filing ↗
- MacroGenics, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics's own proxy. As printed: 2,078,854. View filing ↗
- Ironwood Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. View filing ↗